PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients

No abstract is available for this paper.

• Publication year

  2008

• Venue

  The Pharmacogenomics Journal

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.tpj.6500478PMID 17876342
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population

  2006cited by this paper
• Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel

  2006cited by this paper
• Screening for polymorphisms in the PXR gene in a Dutch population

  2006cited by this paper
• The functional Thr130Ile and Val255Met polymorphisms of the hepatocyte nuclear factor-4alpha (HNF4A): gene associations with type 2 diabetes or altered beta-cell function among Danes.

  2005cited by this paper
• Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics.

  2005cited by this paper
• Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry.

  2005cited by this paper
• A variant 2677A allele of the MDR1 gene affects fexofenadine disposition

  2004cited by this paper
• Genetic variability in CYP3A5 and its possible consequences.

  2004cited by this paper
• CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.

  2004cited by this paper
• Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha.

  2003cited by this paper
• The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4

  2003cited by this paper
• Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes

  2003cited by this paper
• Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4α, GCK and HNF-1α

  2003cited by this paper
• Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.

  2003cited by this paper
• Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus

  2003cited by this paper
• Hepatocyte nuclear factor 4 alpha isoforms originated from the P1 promoter are expressed in human pancreatic beta-cells and exhibit stronger transcriptional potentials than P2 promoter-driven isoforms.

  2003cited by this paper
• T130I mutation in HNF-4α gene is a loss-of-function mutation in hepatocytes and is associated with late-onset Type 2 diabetes mellitus in Japanese subjects

  2003cited by this paper
• The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism.

  2002cited by this paper
• Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.

  2002cited by this paper
• Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations.

  2002cited by this paper
• Pxr, car and drug metabolism

  2002cited by this paper
• Regulation of cyp3a gene transcription by the pregnane x receptor.

  2002cited by this paper
• Maturity-onset diabetes of the young Type 1 (MODY1)-associated mutations R154X and E276Q in hepatocyte nuclear factor 4alpha (HNF4alpha) gene impair recruitment of p300, a key transcriptional co-activator.

  2001cited by this paper
• Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: A study using adenovirus‐mediated antisense targeting

  2001cited by this paper
• Identification of functionally variant MDR1 alleles among European Americans and African Americans

  2001cited by this paper
• The activation function-1 of hepatocyte nuclear factor-4 is an acidic activator that mediates interactions through bulky hydrophobic residues.

  2001cited by this paper
• The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants.

  2001cited by this paper
• Naturally occurring mutations in the human HNF4alpha gene impair the function of the transcription factor to a varying degree.

  2000cited by this paper
• Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

  2000cited by this paper
• Clinical Pharmacokinetics of Docetaxel

  1999cited by this paper
• Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients

  1999cited by this paper
• An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway.

  1998cited by this paper
• Critical Structural Elements and Multitarget Protein Interactions of the Transcriptional Activator AF-1 of Hepatocyte Nuclear Factor 4*

  1998cited by this paper
• The DNA Binding Domain of Hepatocyte Nuclear Factor 4 Mediates Cooperative, Specific Binding to DNA and Heterodimerization with the Retinoid X Receptor α*

  1997cited by this paper
• A Sensitive and Simple High‐Performance Liquid Chromatographic Method for the Determination of Doxorubicin and Its Metabolites in Plasma

  1993cited by this paper

• A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients

  2024cites this paper
• Metabolism-involved drug interactions with traditional Chinese medicines in cardiovascular diseases

  2022cites this paper
• Natural compounds targeting nuclear receptors for effective cancer therapy

  2022cites this paper
• Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy

  2021cites this paper
• Polymorphisms contribute to differences in the effect of rocuronium in Chinese patients

  2021cites this paper
• Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships

  2021cites this paper
• Exploring pharmacogenetics of taxane-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships

  2021cites this paper
• Different treatment efficacies and side effects of cytotoxic chemotherapy

  2020cites this paper
• Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy

  2020cites this paper
• Neutropenia and docetaxel exposure in metastatic castration‐resistant prostate cancer patients: A meta‐analysis and evaluation of a clinical cohort

  2019cites this paper
• Incidence of Febrile Neutropenia in Advanced Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy in Korea and Its Impact on Prognosis

  2019cites this paper
• Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers

  2019cites this paper
• Association of hepatic nuclear factor 4 alpha gene polymorphisms with free Imatinib plasma levels and adverse reactions in Chinese gastrointestinal stromal tumor patients.

  2019cites this paper
• Regional clinical pharmacology trials for Multi-Regional clinical trials

  2018cites this paper
• Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability.

  2018cites this paper
• Taxane Combination Chemotherapy in Breast Cancer: Experience from a Tertiary Cancer Centre in India

  2017cites this paper
• Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries.

  2017cites this paper
• Nuclear receptors and drug metabolism for the personalization of cancer therapy

  2016cites this paper
• Bile Acids as Novel Pharmacological Agents: The Interplay Between Gene Polymorphisms, Epigenetic Factors and Drug Response.

  2016cites this paper
• Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy

  2016cites this paper
• Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach

  2016cites this paper
• Pharmacological and Interventional Approaches for Optimizing Taxane Treatment

  2016cites this paper
• Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.

  2016cites this paper
• Role of the nuclear pregnane X receptor in drug metabolism and the clinical response

  2015cites this paper
• Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients.

  2015cites this paper
• High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial

  2015cites this paper
• Inter-patient variability in docetaxel pharmacokinetics: A review.

  2015cites this paper
• Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer

  2015cites this paper
• Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

  2015cites this paper
• Effects of Pregnane X Receptor Genetic Polymorphisms on Stable Warfarin Doses

  2015cites this paper
• Genetic variation: effect on prostate cancer.

  2014cites this paper
• Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients

  2014cites this paper
• Pregnane X receptor and hepatocyte nuclear factor 4&agr; polymorphisms are cooperatively associated with carbamazepine autoinduction

  2014cites this paper
• Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia

  2014cites this paper
• Association of genetic variants with anti-tuberculosis drug induced hepatotoxicity: a high resolution melting analysis.

  2014cites this paper
• Pharmacogenomic diversity in Singaporean populations and Europeans

  2014cites this paper
• Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients

  2013cites this paper
• Genetic variations of NR1I3 and NR2B1 in Asian populations.

  2013cites this paper
• Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?

  2013cites this paper
• Pregnane X receptor and human malignancy.

  2013cites this paper
• Genetic Variability of PXR in Saudi Arabians

  2013influential citation
• PXR Variants and Artemisinin Use in Vietnamese Subjects: Frequency Distribution and Impact on the Interindividual Variability of CYP3A Induction by Artemisinin

  2012cites this paper
• The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy

  2012cites this paper
• A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers.

  2011cites this paper
• Inter-ethnic differences--how important is it in cancer treatment?

  2011cites this paper
• Level of evidence for therapeutic drug monitoring of taxanes

  2011cites this paper
• Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy

  2011cites this paper
• Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study

  2011cites this paper
• [Not Available].

  2010cites this paper
• Niveau de preuve du suivi thérapeutique pharmacologique du paclitaxel

  2010cites this paper
• Supporting Asian patients with metastatic breast cancer during ixabepilone therapy

  2010cites this paper
• Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.

  2010cites this paper
• Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumab

  2010cites this paper
• Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer

  2010cites this paper
• The impact of microRNAs and alternative splicing in pharmacogenomics

  2009cites this paper
• Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.

  2009cites this paper
• Hematotoxicity: In Vitro and Ex Vivo Compound Profiling

  2009cites this paper
• PXR Pharmacogenetics: Association of Haplotypes with Hepatic CYP3A4 and ABCB1 Messenger RNA Expression and Doxorubicin Clearance in Asian Breast Cancer Patients

  2008cites this paper
• Pharmacogenetics in Breast Cancer Therapy

  2008cites this paper
• Do Single Nucleotide Polymorphisms in Xenobiotic Metabolizing Genes Determine Breast Cancer Susceptibility and Treatment Outcomes?

  2008cites this paper
• Lack of Association of Single-Nucleotide Polymorphisms in Pregnane X Receptor, Hepatic Nuclear Factor 4α, and Constitutive Androstane Receptor with Docetaxel Pharmacokinetics

  2007cites this paper